share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K：重大事件
美股SEC公告 ·  08/23 16:42
Moomoo AI 已提取核心訊息
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has successfully completed the sale of an additional 500 shares of Series B Convertible Preferred Stock to an institutional accredited investor for $500,000 on August 22, 2024. This transaction is part of a partial fourth closing under a Securities Purchase Agreement (SPA) that was previously amended in April 2024. The shares were sold at a 10% discount to their stated value of $1,100 per share. The company's stockholders had approved this issuance at the Annual Meeting on June 17, 2024, in compliance with Nasdaq Listing Rule 5635(d). The rights and preferences of the Series B Preferred Stock have been detailed in prior reports filed with the SEC. The issuance was exempt from registration under the Securities Act of 1933, as it was not a public offering and the purchaser is an accredited investor. Additionally, on the same day, Mangoceuticals' Board of Directors approved an increase in the monthly car allowance for CEO Jacob Cohen from $1,500 to $2,500.
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has successfully completed the sale of an additional 500 shares of Series B Convertible Preferred Stock to an institutional accredited investor for $500,000 on August 22, 2024. This transaction is part of a partial fourth closing under a Securities Purchase Agreement (SPA) that was previously amended in April 2024. The shares were sold at a 10% discount to their stated value of $1,100 per share. The company's stockholders had approved this issuance at the Annual Meeting on June 17, 2024, in compliance with Nasdaq Listing Rule 5635(d). The rights and preferences of the Series B Preferred Stock have been detailed in prior reports filed with the SEC. The issuance was exempt from registration under the Securities Act of 1933, as it was not a public offering and the purchaser is an accredited investor. Additionally, on the same day, Mangoceuticals' Board of Directors approved an increase in the monthly car allowance for CEO Jacob Cohen from $1,500 to $2,500.
德克薩斯州的製藥公司Mangoceuticals, Inc.已於2024年8月22日成功向一家機構認可的投資者出售了500股b系列可轉換優先股，交易金額爲50萬美元。這筆交易是根據之前在2024年4月修改過的《證券購買協議》的第四次部分封閉經過。這些股票以每股1100美元的面值打9折出售。公司股東已於2024年6月17日的年度股東大會上批准了此次發行，以符合納斯達克上市規則5635(d)的要求。b系列優先股的權利和偏好已在之前向美國證券交易委員會提交的報告中詳細說明。此次發行不受1933年證券法註冊要求的限制，因爲它不是公開發行，且購買者是認可投資者。此外，在同一天，Mangoceuticals的董事會批准了首席執行官雅各布·科恩的月度汽車津貼從1500美元增加到2500美元。
德克薩斯州的製藥公司Mangoceuticals, Inc.已於2024年8月22日成功向一家機構認可的投資者出售了500股b系列可轉換優先股，交易金額爲50萬美元。這筆交易是根據之前在2024年4月修改過的《證券購買協議》的第四次部分封閉經過。這些股票以每股1100美元的面值打9折出售。公司股東已於2024年6月17日的年度股東大會上批准了此次發行，以符合納斯達克上市規則5635(d)的要求。b系列優先股的權利和偏好已在之前向美國證券交易委員會提交的報告中詳細說明。此次發行不受1933年證券法註冊要求的限制，因爲它不是公開發行，且購買者是認可投資者。此外，在同一天，Mangoceuticals的董事會批准了首席執行官雅各布·科恩的月度汽車津貼從1500美元增加到2500美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息